Literature DB >> 26185208

Mesenchymal Stem Cells as a Biological Drug for Heart Disease: Where Are We With Cardiac Cell-Based Therapy?

Cristina Sanina1, Joshua M Hare2.   

Abstract

Cell-based treatment represents a new generation in the evolution of biological therapeutics. A prototypic cell-based therapy, the mesenchymal stem cell, has successfully entered phase III pivotal trials for heart failure, signifying adequate enabling safety and efficacy data from phase I and II trials. Successful phase III trials can lead to approval of a new biological therapy for regenerative medicine.
© 2015 American Heart Association, Inc.

Entities:  

Keywords:  cell- and tissue-based therapy; chronic heart failure; clinical trial; heart disease; mesenchymal stem cells

Mesh：

Year:  2015        PMID： 26185208      PMCID： PMC4571454          DOI： 10.1161/CIRCRESAHA.117.306306

Source DB:  PubMed          Journal:  Circ Res        ISSN： 0009-7330            Impact factor:   17.367


  22 in total

1.  A tale of two drugs.

Authors: 
Journal:  Nat Rev Drug Discov       Date:  2006-10       Impact factor: 84.694

2.  Bone Marrow Mononuclear Cell Therapy and Granulocyte Colony-Stimulating Factor for Acute Myocardial Infarction: Is it Time to Reconsider?

Authors:  Joshua M Hare; Cristina Sanina
Journal:  J Am Coll Cardiol       Date:  2015-06-09       Impact factor: 24.094

3.  Clinical development success rates for investigational drugs.

Authors:  Michael Hay; David W Thomas; John L Craighead; Celia Economides; Jesse Rosenthal
Journal:  Nat Biotechnol       Date:  2014-01       Impact factor: 54.908

Review 4.  Lessons learned from the fate of AstraZeneca's drug pipeline: a five-dimensional framework.

Authors:  David Cook; Dearg Brown; Robert Alexander; Ruth March; Paul Morgan; Gemma Satterthwaite; Menelas N Pangalos
Journal:  Nat Rev Drug Discov       Date:  2014-05-16       Impact factor: 84.694

Review 5.  Use of mesenchymal stem cells for therapy of cardiac disease.

Authors:  Vasileios Karantalis; Joshua M Hare
Journal:  Circ Res       Date:  2015-04-10       Impact factor: 17.367

6.  Enhanced effect of combining human cardiac stem cells and bone marrow mesenchymal stem cells to reduce infarct size and to restore cardiac function after myocardial infarction.

Authors:  Adam R Williams; Konstantinos E Hatzistergos; Benjamin Addicott; Fred McCall; Decio Carvalho; Viky Suncion; Azorides R Morales; Jose Da Silva; Mark A Sussman; Alan W Heldman; Joshua M Hare
Journal:  Circulation       Date:  2012-12-05       Impact factor: 29.690

7.  Transendocardial mesenchymal stem cells and mononuclear bone marrow cells for ischemic cardiomyopathy: the TAC-HFT randomized trial.

Authors:  Alan W Heldman; Darcy L DiFede; Joel E Fishman; Juan P Zambrano; Barry H Trachtenberg; Vasileios Karantalis; Muzammil Mushtaq; Adam R Williams; Viky Y Suncion; Ian K McNiece; Eduard Ghersin; Victor Soto; Gustavo Lopera; Roberto Miki; Howard Willens; Robert Hendel; Raul Mitrani; Pradip Pattany; Gary Feigenbaum; Behzad Oskouei; John Byrnes; Maureen H Lowery; Julio Sierra; Mariesty V Pujol; Cindy Delgado; Phillip J Gonzalez; Jose E Rodriguez; Luiza Lima Bagno; Didier Rouy; Peter Altman; Cheryl Wong Po Foo; Jose da Silva; Erica Anderson; Richard Schwarz; Adam Mendizabal; Joshua M Hare
Journal:  JAMA       Date:  2014-01-01       Impact factor: 56.272

Review 8.  Discrepancies in autologous bone marrow stem cell trials and enhancement of ejection fraction (DAMASCENE): weighted regression and meta-analysis.

Authors:  Alexandra N Nowbar; Michael Mielewczik; Maria Karavassilis; Hakim-Moulay Dehbi; Matthew J Shun-Shin; Siana Jones; James P Howard; Graham D Cole; Darrel P Francis
Journal:  BMJ       Date:  2014-04-28

9.  A randomized, open-label, multicenter trial for the safety and efficacy of adult mesenchymal stem cells after acute myocardial infarction.

Authors:  Jun-Won Lee; Seung-Hwan Lee; Young-Jin Youn; Min-Soo Ahn; Jang-Young Kim; Byung-Su Yoo; Junghan Yoon; Woocheol Kwon; In-Soo Hong; Kyounghoon Lee; Jun Kwan; Keum Soo Park; Donghoon Choi; Yang Soo Jang; Mun K Hong
Journal:  J Korean Med Sci       Date:  2013-12-26       Impact factor: 2.153

10.  The origin of human mesenchymal stromal cells dictates their reparative properties.

Authors:  Nili Naftali-Shani; Ayelet Itzhaki-Alfia; Natalie Landa-Rouben; David Kain; Radka Holbova; Shimrit Adutler-Lieber; Natali Molotski; Elad Asher; Avishay Grupper; Eran Millet; Ariel Tessone; Eyal Winkler; Jens Kastrup; Micha S Feinberg; Dov Zipori; Meirav Pevsner-Fischer; Ehud Raanani; Jonathan Leor
Journal:  J Am Heart Assoc       Date:  2013-09-30       Impact factor: 5.501
View more
  30 in total

1.  Intravenous administration of allogeneic Wharton jelly-derived mesenchymal stem cells for treatment of dogs with congestive heart failure secondary to myxomatous mitral valve disease.

Authors:  Vicky K Yang; Dawn M Meola; Airiel Davis; Bruce Barton; Andrew M Hoffman
Journal:  Am J Vet Res       Date:  2021-06       Impact factor: 1.156

2.  Allogeneic Precursor Cells for Systolic Heart Failure: A Need for Mechanisms in Humans.

Authors:  Stephen Farris; April Stempien-Otero
Journal:  Circ Res       Date:  2015-08-28       Impact factor: 17.367

Review 3.  Exosomes Generated From iPSC-Derivatives: New Direction for Stem Cell Therapy in Human Heart Diseases.

Authors:  Ji-Hye Jung; Xuebin Fu; Phillip C Yang
Journal:  Circ Res       Date:  2017-01-20       Impact factor: 17.367

4.  A methylcellulose and collagen based temperature responsive hydrogel promotes encapsulated stem cell viability and proliferation in vitro.

Authors:  Christina Payne; Eimear B Dolan; Janice O'Sullivan; Sally-Ann Cryan; Helena M Kelly
Journal:  Drug Deliv Transl Res       Date:  2017-02       Impact factor: 4.617

5.  Stepwise morphological changes and cytoskeletal reorganization of human mesenchymal stem cells treated by short-time cyclic uniaxial stretch.

Authors:  Azim Parandakh; Mohammad Tafazzoli-Shadpour; Mohammad-Mehdi Khani
Journal:  In Vitro Cell Dev Biol Anim       Date:  2017-02-15       Impact factor: 2.416

6.  Synergistic Effects of Combined Cell Therapy for Chronic Ischemic Cardiomyopathy.

Authors:  Vasileios Karantalis; Viky Y Suncion-Loescher; Luiza Bagno; Samuel Golpanian; Ariel Wolf; Cristina Sanina; Courtney Premer; Anthony J Kanelidis; Frederic McCall; Bo Wang; Wayne Balkan; Jose Rodriguez; Marcos Rosado; Azorides Morales; Konstantinos Hatzistergos; Makoto Natsumeda; Irene Margitich; Ivonne Hernandez Schulman; Samirah A Gomes; Muzammil Mushtaq; Darcy L DiFede; Joel E Fishman; Pradip Pattany; Juan Pablo Zambrano; Alan W Heldman; Joshua M Hare
Journal:  J Am Coll Cardiol       Date:  2015-11-03       Impact factor: 24.094

7.  Is the regulation of SIRT1 by miRNA-34a the key to mesenchymal stem cell survival?

Authors:  Michael A Bellio; Wayne Balkan; Joshua M Hare; Ivonne Hernandez Schulman
Journal:  Ann Transl Med       Date:  2016-06

8.  What Is the Future of Cell-Based Therapy for Acute Myocardial Infarction.

Authors:  Bryon A Tompkins; Makoto Natsumeda; Wayne Balkan; Joshua M Hare
Journal:  Circ Res       Date:  2017-01-20       Impact factor: 17.367

9.  A Deep Proteome Analysis Identifies the Complete Secretome as the Functional Unit of Human Cardiac Progenitor Cells.

Authors:  Sudhish Sharma; Rachana Mishra; Grace E Bigham; Brody Wehman; Mohd M Khan; Huichun Xu; Progyaparamita Saha; Young Ah Goo; Srinivasa Raju Datla; Ling Chen; Mohan E Tulapurkar; Bradley S Taylor; Peixin Yang; Sotirios Karathanasis; David R Goodlett; Sunjay Kaushal
Journal:  Circ Res       Date:  2016-12-01       Impact factor: 17.367

10.  Mesenchymal Stem Cell-Mediated Autophagy Inhibition.

Authors:  Benjamin P Woodall; Åsa B Gustafsson
Journal:  Circ Res       Date:  2018-08-17       Impact factor: 17.367
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.